96 related articles for article (PubMed ID: 2866940)
1. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
Pan JB
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):205-8. PubMed ID: 2866940
[No Abstract] [Full Text] [Related]
2. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Xu DL; Yu WC; Pan GB; Chen SD
Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
[TBL] [Abstract][Full Text] [Related]
3. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
Case TC; Snider SR; Hruby VJ; Rockway T
Life Sci; 1985 Jul; 36(26):2531-7. PubMed ID: 2861549
[TBL] [Abstract][Full Text] [Related]
4. Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.
Barbeau A; Roy M; Kastin AJ
Can Med Assoc J; 1976 Jan; 114(2):120-2. PubMed ID: 3279
[TBL] [Abstract][Full Text] [Related]
5. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
[TBL] [Abstract][Full Text] [Related]
6. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
Gonce M; Barbeau A
Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
[TBL] [Abstract][Full Text] [Related]
7. [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].
Carolei A; Meco G; Casacchia M; Agnoli A
Acta Neurol (Napoli); 1976; 31(4):475-8. PubMed ID: 16441
[No Abstract] [Full Text] [Related]
8. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.
Chiu S; Mishra RK
Eur J Pharmacol; 1979 Jan; 53(2):119-25. PubMed ID: 32058
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.
Mishra RK; Chiu S; Chiu P; Mishra CP
Methods Find Exp Clin Pharmacol; 1983; 5(4):203-33. PubMed ID: 6136640
[No Abstract] [Full Text] [Related]
10. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
Albrecht HP; Hofman HP; Klebe G; Kreiskott H
Boll Chim Farm; 1991 Feb; 130(2):55-9. PubMed ID: 1678611
[TBL] [Abstract][Full Text] [Related]
11. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
Mishra RK
Nutr Health; 1984; 3(3):175-87. PubMed ID: 6152723
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
Barbeau A
Lancet; 1975 Oct; 2(7937):683-4. PubMed ID: 52054
[TBL] [Abstract][Full Text] [Related]
13. [Peptide neurotransmitters and extrapyramidal disorders].
Tan MX
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):246-7. PubMed ID: 2416519
[No Abstract] [Full Text] [Related]
14. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
Przuntek H
Med Klin; 1979 Jul; 74(28-29):1077-83. PubMed ID: 39230
[No Abstract] [Full Text] [Related]
16. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
Caraceni T; Parati EA; Girotti F; Celano I; Frigerio C; Cocchi D; Müller EE
Psychopharmacology (Berl); 1979 Jun; 63(3):217-22. PubMed ID: 39308
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor density remains constant in treated Parkinson's disease.
Guttman M; Seeman P; Reynolds GP; Riederer P; Jellinger K; Tourtellotte WW
Ann Neurol; 1986 May; 19(5):487-92. PubMed ID: 2940960
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
Quock RM; Lucas TS; Hartl TJ
Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
[TBL] [Abstract][Full Text] [Related]
19. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
Campanella G; Pennetta R
Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
[No Abstract] [Full Text] [Related]
20. Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels.
Petersson M; Uvnäs-Moberg K
Physiol Behav; 2004 Dec; 83(3):475-81. PubMed ID: 15581670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
